BBIO News and Press, BridgeBio Pharma Inc.

2026-07-02 09:44:33 ET Shares of endocrine therapy concern Ascendis Pharma (ASND) enjoyed a 30-month rally that has seen the shares more than triple, owing to the performance of hormone therapy Yorvipath. Recent approval of its once-weekly injectable achondroplasia treatment Yuviwel...

- Acoramidis initiation was associated with rapid kidney-protective activity as exhibited in a hemodynamically mediated, reversible eGFR dip and a placebo-corrected 15.5% reduction in UACR by Day 28 (P<0.05), with no kidney-related adverse events observed in these post-hoc analyses -Treatm...

2026-07-01 07:57:01 ET More on BridgeBio Pharma BridgeBio: 3 New Drug Approvals In Sight Outweigh Attruby Issues, Still Bullish BridgeBio Pharma, Inc. (BBIO) Presents at Bank of America Global Healthcare Conference 2026 Transcript BridgeBio Pharma, Inc. (BBIO) Presen...

- Preferred equity investment led by Sixth Street and with participation from HealthCare Royalty, a business of KKR, with an initial conversion price of approximately $138 per share (more than 100% premium to Company’s 30-day VWAP) - The financing significantly strengthens the Company&...

2026-07-01 00:19:46 ET Read the full article on Seeking Alpha For further details see: BridgeBio Pharma reportedly in talks for $1B preferred equity from KKR, Sixth Street

2026-06-29 14:04:23 ET Investment Overview BridgeBio Pharma, Inc. ( BBIO ) stock has barely budged since I covered the company last for Seeking Alpha in late April , assigning a Buy rating. The stock is worth ~$72 per share in early trading today, and the market cap valuatio...

- Phase 3 PROPEL 3 data published today in NEJM were simultaneously presented at ICCBH in a late-breaking oral presentation; presentation includes new arm span Z-score data showing a statistically significant improvement versus placebo (LS mean +0.37 SD; p<0.0001), the first and only statistic...

2026-06-24 10:39:47 ET More on Spyre Therapeutics Spyre Therapeutics, Inc. (SYRE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript Spyre Therapeutics: Strong SPY001 Data Set Up A Catalyst-Rich 2026 Spyre Therapeutics, Inc. (SYRE) Dis...

2026-06-22 12:57:19 ET NTHI Joins a Growing Group of Companies Pursuing Parallel Global Regulatory Strategies, as International Approvals Have Helped Launch Major Drug Successes DENVER, Colo. ( 247marketnews.com ) -- NeOnc Technologies Holdings (NASDAQ:NTHI) rema...

PALO ALTO, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additiona...